These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

781 related items for PubMed ID: 9883755

  • 1. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD, Hsu DT, Kichuk MR, Garvin JH, Stolar CJ, Haddad J, Stylianos S, Michler RE, Chadburn A, Knowles DM, Addonizio LJ.
    J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
    [Abstract] [Full Text] [Related]

  • 2. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [Abstract] [Full Text] [Related]

  • 3. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 4. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C, Pollock-Barziv SM, Holmes C, Weitzman S, Allen U, Clarizia NA, Ngan BY, McCrindle BW, Dipchand AI.
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [Abstract] [Full Text] [Related]

  • 5. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F.
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [Abstract] [Full Text] [Related]

  • 6. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
    Doesch AO, Konstandin M, Celik S, Kristen A, Frankenstein L, Sack FU, Schnabel P, Schnitzler P, Katus HA, Dengler TJ.
    Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
    [Abstract] [Full Text] [Related]

  • 7. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 8. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K.
    Scand J Infect Dis; 2007 Oct; 39(3):235-44. PubMed ID: 17366054
    [Abstract] [Full Text] [Related]

  • 9. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA.
    Clin Transplant; 2006 Oct; 20(3):389-93. PubMed ID: 16824159
    [Abstract] [Full Text] [Related]

  • 10. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
    Wu JF, Ho MC, Ni YH, Chen HL, Lu CY, Hsu HY, Lee PH, Chang MH.
    Transplantation; 2009 Mar 15; 87(5):758-62. PubMed ID: 19295323
    [Abstract] [Full Text] [Related]

  • 11. [Epstein-Barr virus infection in patients after bone marrow and heart transplantation].
    Zawilińska B, Gruszka K, Piatkowska-Jakubas B, Garlicki M, Skotnicki A.
    Przegl Epidemiol; 2001 Mar 15; 55 Suppl 3():52-5. PubMed ID: 11984959
    [Abstract] [Full Text] [Related]

  • 12. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E, Cooperative Study Group on PTLDs.
    Haematologica; 2002 Jan 15; 87(1):67-77. PubMed ID: 11801467
    [Abstract] [Full Text] [Related]

  • 13. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
    Tai CC, Curtis JL, Szmuszkovicz JR, Horn MV, Ford HR, Woo MS, Wang KS.
    J Pediatr Surg; 2008 Dec 15; 43(12):2174-7. PubMed ID: 19040929
    [Abstract] [Full Text] [Related]

  • 14. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C, Giacchino F, Bergallo M, Bonello F, Bollero C, Segoloni GP, Cavallo R.
    G Ital Nefrol; 2003 Dec 15; 20(2):170-5. PubMed ID: 12746803
    [Abstract] [Full Text] [Related]

  • 15. Adenotonsillar hypertrophy and Epstein-Barr virus in pediatric organ transplant recipients.
    Shapiro NL, Strocker AM.
    Laryngoscope; 2001 Jun 15; 111(6):997-1001. PubMed ID: 11404611
    [Abstract] [Full Text] [Related]

  • 16. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N, Gabdrakhmanova L, Hammer M, Rosenberger C, Oppert M, Volk HD, Reinke P.
    Transpl Infect Dis; 2005 Jun 15; 7(3-4):133-6. PubMed ID: 16390402
    [Abstract] [Full Text] [Related]

  • 17. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL, Heubi JE, Bucuvalas JC, Gross TG, Ryckman FC, Alonso MH, Balistreri WF, Hornung RW.
    Transplantation; 2003 Apr 15; 75(7):987-93. PubMed ID: 12698085
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immunohistochemical analysis and Epstein-Barr virus in the tonsils of transplant recipients and healthy controls.
    Mowry SE, Strocker AM, Chan J, Takehana C, Kalantar N, Bhuta S, Shapiro NL.
    Arch Otolaryngol Head Neck Surg; 2008 Sep 15; 134(9):936-9. PubMed ID: 18794437
    [Abstract] [Full Text] [Related]

  • 20. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A, Jiménez L, Aranda I, Alvarez L, González M, Rocamora N, Olivares J.
    Nefrologia; 2002 Sep 15; 22(5):463-9. PubMed ID: 12497748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.